Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2011 1
2012 1
2014 1
2015 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans biofilms.
De Cremer K, Lanckacker E, Cools TL, Bax M, De Brucker K, Cos P, Cammue BP, Thevissen K. De Cremer K, et al. Antimicrob Agents Chemother. 2015 Jan;59(1):421-6. doi: 10.1128/AAC.04229-14. Epub 2014 Nov 3. Antimicrob Agents Chemother. 2015. PMID: 25367916 Free PMC article.
As resistance to azoles (the preferred treatment) is occurring, we aimed at identifying compounds that increase the activity of miconazole against Candida albicans biofilms. We screened 1,600 compounds of a drug-repositioning library in combination with a subinhibitory con …
As resistance to azoles (the preferred treatment) is occurring, we aimed at identifying compounds that increase the activity of miconazol
17-Octadecynoic acid improves contractile response to angiotensin II by releasing vasocontrictor prostaglandins.
Jerez S, Sierra L, de Bruno MP. Jerez S, et al. Prostaglandins Other Lipid Mediat. 2012 Jan;97(1-2):36-42. doi: 10.1016/j.prostaglandins.2011.07.008. Epub 2011 Aug 5. Prostaglandins Other Lipid Mediat. 2012. PMID: 21839852
In arteries with the endothelium-intact (E+) the CYP-inhibitor, 17-octadecynoic acid (17 ODYA), increased the efficacy to angiotensin II (17-ODYA-effect) as well as simultaneous incubation with miconazole (epoxygenase-inhibitor) and CAY 10434 (omega-hydroxylase-inhibitor). …
In arteries with the endothelium-intact (E+) the CYP-inhibitor, 17-octadecynoic acid (17 ODYA), increased the efficacy to angiotensin II (17 …